AKUSAkouos, Inc.

Nasdaq akouos.com


$ 13.30 $ 0.14 (1.06 %)    

Wednesday, 30-Nov-2022 15:58:54 EST
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 13.29
$ 13.15 x 500
$ 13.33 x 800
-- - --
$ 2.32 - $ 13.60
1,790,496
na
457.01M
$ -0.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2022 09-30-2022 10-Q
2 08-15-2022 06-30-2022 10-Q
3 05-12-2022 03-31-2022 10-Q
4 03-29-2022 12-31-2021 10-K
5 11-12-2021 09-30-2021 10-Q
6 08-12-2021 06-30-2021 10-Q
7 05-13-2021 03-31-2021 10-Q
8 03-29-2021 12-31-2020 10-K
9 11-12-2020 09-30-2020 10-Q
10 08-13-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 around-375-million-bet-on-this-biotechnology-stock-check-out-these-4-stocks-insiders-are-buying

Although US stocks closed mixed on Thursday, there were a few notable insider trades.

 akouos-q3-eps-054-up-from-067-yoy

Akouos (NASDAQ:AKUS) reported quarterly losses of $(0.54) per share. This is a 19.4 percent increase over losses of $(0.67) per...

 benzingas-top-ratings-upgrades-downgrades-for-october-19-2022

Upgrades

 piper-sandler-downgrades-akouos-to-neutral-lowers-price-target-to-13

Piper Sandler analyst Yasmeen Rahimi downgrades Akouos (NASDAQ:AKUS) from Overweight to Neutral and lowers the price target ...

 william-blair-downgrades-akouos-to-market-perform

William Blair analyst Sami Corwin downgrades Akouos (NASDAQ:AKUS) from Outperform to Market Perform.

 why-quoin-pharmaceuticals-shares-jumped-by-more-than-44-here-are-57-biggest-movers-from-yesterday

Gainers COMSovereign Holding Corp. (NASDAQ: COMS) shares jumped 170.1% to close at $0.1194 on Tuesday after gaining 4% on Mo...

 carnival-amazon-iamgold-and-other-big-gainers-from-tuesday

U.S. stocks closed higher on Monday, with the Dow Jones gaining more than 300 points. Here is the list of some big stocks recor...

 crude-oil-drops-over-2-akouos-shares-spike-higher

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 300 points on Tuesday.

 nasdaq-rises-over-100-points-goldman-sachs-tops-q3-views

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Tuesday.

Core News & Articles

https://techydailynews.com/2022/10/18/decibel-therapeutics-hears-it-may-be-a-takeout-target-after-lilly-acquisition-of-akouos/ ...

 why-akouos-shares-are-trading-sharply-higher-here-are-36-stocks-moving-in-tuesdays-mid-day-session

Gainers

 health-care-company-eli-lilly-announces-acquisition-of-akouos

Eli Lilly (NYSE:LLY) has announced an acquisition of Akouos (NASDAQ:AKUS) that is expected to be completed in Q4 of 2022.

 us-stocks-extend-mondays-gains-dow-jumps-over-500-points

U.S. stocks traded higher this morning, with the Dow Jones gaining over 500 points on Tuesday. The Dow also climbed around 550 ...

 hc-wainwright--co-downgrades-akouos-to-neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Akouos (NASDAQ:AKUS) from Buy to Neutral.

 12-health-care-stocks-moving-in-tuesdays-pre-market-session

Gainers Akouos (NASDAQ:AKUS) shares moved upwards by 86.2% to $13.05 during Tuesday's pre-market session. The company...

 aveo-pharmaceuticals-akouos-and-some-other-big-stocks-moving-higher-in-todays-pre-market-session

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Core News & Articles

Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with...

 why-senti-biosciences-shares-jumped-over-50-here-are-79-biggest-movers-from-yesterday

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities in...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION